



VIRGIL

VIRGIL Annual International Symposium on Antiviral Drug Resistance

Wednesday May 23rd, 2007
Lyon, France

CENTRE DE CONGRES ESPACE TETE D'OR
103, boulevard Stalingrad
69100 Lyon –Villeurbanne, France

Programme

Scientific Committee

Fabien Zoulim, INSERM, France
Bruno Lina, Université de Claude Bernard Lyon 1, France
Michael Manns, Medizinische Hochschule, Germany
Jean-Michel Pawlotsky, Université Paris XII Val-de-Marne, France
Maria Zambon, Health Protection Agency, UK
Ralf Bartenschlager, University of Heidelberg, Germany
Alan Hay, National Institute for Medical Research, UK
Helmut Diepolder, Ludwig Maximilians Universität München, Germany
Stefan Ludwig, Institute of Molecular Medicine, Germany
Johan Neyts, Rega Institute, Katholieke Universiteit Leuven, Belgium
Willy Spaan, Leiden University, The Netherlands
John Oxford, Retroscreen Virology, UK
Jean-Marie Cohen, Open Rome, France
Solko Schalm, LiverDoc, Netherlands

Third Virgil symposium on antiviral drug resistance management

9.00 am to 9.15 am. Main achievements of the VIRGIL network

Professor Fabien Zoulim, VIRGIL Network co-ordinator

9.15 am to 11.00 am: Clinical impact of drug resistance

Chairs: Bruno Lina, Jean-Marie Cohen

Maria Zambon (London, UK): Resistance to anti influenza drugs: the global picture (20 min)

Keynote lecture

W. Gerlich (Germany): Therapeutic targets in the life cycle of hepatitis B virus (20 min)

Guy Vernet (Lyon, France): The DNA chip technology as a novel tool for the detection of HBV resistant mutants (20 min)

Keynote lecture

P. Lampertico (Milan, Italy): Management of HBV resistance to lamivudine, the Italian experience (20 min)

Round table discussion

11.00 am to 11.15 am : coffee break

11.15 am to 1.00 pm : Understanding the mechanism of drug resistance

Chairs: Christian Trepo, Solko Schalm

John Oxford (London, UK): New insight on drug resistance in animal models of influenza (20 min)

Keynote lecture

Jennifer McKimm Breschkin (CSIRO Molecular and Health Technologies, Australia): Resistance to Influenza Virus Neuraminidase Inhibitors (20 min)

Ralf Bartenschlager (Heidelberg, Germany): Characterization of the early and late steps of HCV replication: a new target for antivirals? (20 min)

Michael Nassal (Freiburg, Germany): In vitro reconstitution of HBV polymerase enzymatic activity (20 min)

Round table discussion

1.00 pm to 2.00 pm : Lunch break

2.00 pm to 3.45 pm : New drugs to combat drug resistance

Chairs: Fabien Zoulim, Willy Spaan

Alan Hay (London): Structure of N1 neuraminidase and its implications for drug discovery (20 min)

François Penin (Lyon, France): Three dimensional structures of HCV enzymes and new targets for antiviral therapy (20 min)

Johan Neyts (Leuven, Belgium): New insight on anti-HCV combination therapy from studies in the replicon model (20 min)

Markus Cornberg (Hannover, Germany): Future treatment of HCV – How to avoid resistance ? (20 min)

Round table discussion

3.45 pm to 4.00 pm : coffee break

4.00 pm to 6.00 pm : Host response and treatment failure

Chairs: Stephan Ludwig, Helmut Diepolder

Keynote Lecture

Eleanor Fish (Division of Cellular & Molecular Biology, Toronto General Research Institute, Canada): Broad Spectrum Antiviral Strategy: Proof of Principle (20 min)

Oliver Planz (Tubingen Germany): Intracellular signalling pathway and influenza virus infection (15 min)

Matti Sallberg (Stockholm, Sweden): Role of Hepatitis C virus NS3/4A protein in immune evasion (15 min)

Vicente Soriano (Madrid, Spain): Management of HCV therapy in HIV co-infected patients (20 min)

Keynote lecture

Rudi Pauwels (Lausanne): Concepts for drug discovery in infectious diseases ; the case of HIV (20 min)

Round table discussion

6.00 pm: Conclusions

Fabien Zoulim

Gala Dinner